Search Results for "lateral"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for lateral. Results 111 to 120 of 278 total matches.

Rituximab for Non-Hodgkins Lymphoma

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998  (Issue 1029)
) and diphenhydramine (Benadryl, and others). Thrombocytopenia, anemia and neutropenia can occur later, but are less ...
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
Med Lett Drugs Ther. 1998 Jun 19;40(1029):65-6 |  Show IntroductionHide Introduction

New Monoclonal Antibodies to Prevent Transplant Rejection

   
The Medical Letter on Drugs and Therapeutics • Sep 25, 1998  (Issue 1036)
of transplantation and the other four days later, were associated with a 30% incidence of acute rejection within six ...
Basiliximab (Simulect - Novartis) and daclizumab (Zenapax - Roche), two mouse/human monoclonal antibodies that block the interleukin-2 (IL-2) receptor on Tlymphocytes, have been approved by the FDA for use in the prevention of acute renal transplant rejection. Both drugs are used with cyclosporine (Sandimmune; Neoral) and corticosteroids. An all-murine anti-CD3 monoclonal antibody, muromonab-CD3 (Orthoclone OKT3), has been available in the USA for many years for treatment of transplant rejection, and has also been used with some success for prophylaxis (MI Wilde and KL Goa, Drugs,...
Med Lett Drugs Ther. 1998 Sep 25;40(1036):93-4 |  Show IntroductionHide Introduction

Thalidomide

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998  (Issue 1038)
as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug ...
Thalidomide (Thalomid - Celgene), a synthetic derivative of glutamic acid, has been approved by the FDA for use in treatment of leprosy. Thalidomide was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug has since been found to be effective for several different indications.
Med Lett Drugs Ther. 1998 Oct 23;40(1038):103-4 |  Show IntroductionHide Introduction

Plan B: A Progestin-Only Emergency Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2000  (Issue 1070)
be taken as soon as possible after coitus, but at least within 72 hours, and the other 12 hours later ...
The FDA has approved marketing of Plan B (Women's Capital Corporation), an emergency contraceptive "pill pack"that contains two 0.75-mg tablets of levonorgestrel.
Med Lett Drugs Ther. 2000 Jan 24;42(1070):10 |  Show IntroductionHide Introduction

Ophthalmic Cyclosporine (Restasis) for Dry Eyes

   
The Medical Letter on Drugs and Therapeutics • May 26, 2003  (Issue 1157)
instilling the drops, but can be replaced 15 minutes later. A package of 32 preservative-free vials labelled ...
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the causes of dry eye disease and includes sections on the pharmacology, adverse effects and clinical trial results for ophthalmic cyclosporine. Cost information and recommendations for administering the drug are also presented. The review concludes with an overall assessment of the drug's efficacy, safety and cost.
Med Lett Drugs Ther. 2003 May 26;45(1157):42-3 |  Show IntroductionHide Introduction

Topiramate Extended-Release (Trokendi XR) for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2013  (Issue 1428)
capsules; plasma levels may be markedly higher soon after dosing and subtherapeutic later in the day ...
The FDA has approved a once-daily extended-release (ER) formulation of the antiepileptic topiramate (Trokendi XR – Supernus) for initial monotherapy in patients ≥10 years old with partial onset seizures or primary generalized tonic-clonic seizures and for adjunctive therapy in patients ≥6 years old with partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. Topiramate has been available for many years as an immediate-release (IR) formulation (Topamax, and generics) for the same indications in patients ≥2...
Med Lett Drugs Ther. 2013 Oct 28;55(1428):87-8 |  Show IntroductionHide Introduction

In Brief: A New Glucagon Injection (Gvoke) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
minutes later. ■ 1. Glucagon nasal powder (Baqsimi) for severe hypoglycemia. Med Lett Drugs Ther 2019 ...
The FDA has approved a new formulation of glucagon (Gvoke – Xeris) for subcutaneous treatment of severe hypoglycemia in patients ≥2 years old with diabetes. Conscious patients with symptoms of hypoglycemia can take oral glucose. Glucagon is usually administered by a caregiver to an unresponsive patient. The new formulation is available in a single-use prefilled syringe (Gvoke PFS) and is expected to become available in a single-use auto-injector (Gvoke HypoPen) in 2020. Unlike previously available injectable glucagon products (Glucagon Emergency Kit, and others), Gvoke does not...
Med Lett Drugs Ther. 2019 Nov 18;61(1585):186 |  Show IntroductionHide Introduction

In Brief: Risdiplam (Evrysdi) for Spinal Muscular Atrophy (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021  (Issue 1629)
, double-blind trial (SUNFISH) in patients 2-25 years old (later-onset SMA; type 2 or 3 SMA). Both trials ...
Risdiplam (Evrysdi – Genentech), a survival of motor neuron 2 (SMN2) splicing modifier, has been approved by the FDA for oral treatment of spinal muscular atrophy (SMA) in patients ≥2 months old. It is the first oral drug to be approved in the US for treatment of SMA; nusinersen (Spinraza), an intrathecally administered SMN2-directed antisense oligonucleotide, and onasemnogene abeparvovec (Zolgensma), an IV adeno-associated virus vector-based gene therapy, were approved earlier.
Med Lett Drugs Ther. 2021 Jul 26;63(1629):e1-2 |  Show IntroductionHide Introduction

COVID-19 Update: Metformin to Prevent Long Covid?

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
metformin for 2 weeks were less likely than those who took placebo to later report a diagnosis of long ...
Results from a double-blind trial suggest that off-label use of the oral antihyperglycemic drug metformin in patients with COVID-19 may decrease the risk of post-acute sequelae of SARS-CoV-2 infection ("long COVID").
Med Lett Drugs Ther. 2023 May 29;65(1677):87-8   doi:10.58347/tml.2023.1677e |  Show IntroductionHide Introduction

Two New Drugs for Skin and Skin Structure Infections

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014  (Issue 1449)
, then 14 days (2 doses Dalvance (Durata) 500 mg 1 wk later 1 week apart) 1490.004 Daptomycin3 – 500 mg ...
The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin (Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide antibiotic similar to telavancin (Vibativ). Tedizolid phosphate (Sivextro – Cubist) is an IV and oral oxazolidinone antibacterial drug similar to linezolid (Zyvox). A third IV antibiotic, oritavancin (Orbactiv), recently approved by the FDA for the same indication, will be reviewed in a future...
Med Lett Drugs Ther. 2014 Aug 18;56(1449):73-5 |  Show IntroductionHide Introduction